Site‐Specific Quadruple‐Functionalised Antibodies
Angewandte Chemie International Edition · 27.01.2025 · 64 (5)
DOI: 10.1002/anie.202417620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 16.11.2024. Verfasst von Toby Journeaux und 7 weiteren Autor:innen. Beteiligte Einrichtung: Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK. Hauptthemen laut MEDLINE: Immunoconjugates, Antibodies, Monoclonal, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Molecular Biology Organization, AstraZeneca, Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) are a growing class of chemotherapeutic agents that have yielded striking clinical successes. However, the efficacy of ADCs often suffers from issues associated with tumor heterogeneity and resistance. To overcome these problems, a new generation of ADCs comprising a single monoclonal antibody with multiple different payloads attached, termed multi‐payload ADCs, have been developed. Here we deploy multiple orthogonal site‐specific protein modification strategies to generate highly homogeneous multi‐functionalised antibody conjugates comprising up to four different functionalities installed at four unique sites on the antibody. This work, which includes the use of a site‐specific cyclopropenone (CPO)‐based reagent, represents the first example of a homogeneous multi‐payload ADC with a payload count greater than two, and thereby facilitates the development of the next generation of ADCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
- Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK.
- Analytical Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK.
ORCID-Profile: Gonçalo J L Bernardes
Förderung
- European Molecular Biology Organization
- AstraZeneca
- Engineering and Physical Sciences Research Council
Zitieren
APA
Journeaux, T., Geeson, M. B., Murray, T. V., Papworth, M. A., Gothard, M., Kettle, J. G., Vasco, A. V., & Bernardes, G. J. L. (2025). Site‐Specific Quadruple‐Functionalised Antibodies. Angewandte Chemie International Edition, 64(5). https://doi.org/10.1002/anie.202417620
Vancouver
Journeaux T, Geeson MB, Murray TV, Papworth MA, Gothard M, Kettle JG, et al. Site‐Specific Quadruple‐Functionalised Antibodies. Angewandte Chemie International Edition. 2025;64(5). doi:10.1002/anie.202417620
BibTeX
@article{Journeaux2025,
author = {Journeaux, Toby and Geeson, Michael B and Murray, Thomas V and Papworth, Monika A and Gothard, Matt and Kettle, Jason G and Vasco, Aldrin V and Bernardes, Gonçalo J L},
title = {Site‐Specific Quadruple‐Functionalised Antibodies},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {5},
doi = {10.1002/anie.202417620}
}
EUVIMED